Shares of ResMed Inc. (NYSE:RMD) have been assigned a consensus rating of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $203.67.
RMD has been the topic of several recent research reports. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “hold” rating and set a $222.00 price objective on the stock. in a research report on Wednesday, December 30th. Needham & Company LLC raised shares of ResMed from a “hold” rating to a “buy” rating and set a $229.00 target price on the stock in a research note on Monday, March 22nd.
In related news, CFO Brett Sandercock sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, January 11th. The shares were sold at an average price of $218.70, for a total transaction of $546,750.00. Following the completion of the sale, the chief financial officer now directly owns 100,600 shares in the company, valued at $22,001,220. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Robert Andrew Douglas sold 938 shares of the firm’s stock in a transaction that occurred on Friday, January 15th. The stock was sold at an average price of $212.86, for a total transaction of $199,662.68. Following the sale, the chief operating officer now owns 12,602 shares of the company’s stock, valued at $2,682,461.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 19,506 shares of company stock worth $3,893,437. 1.33% of the stock is currently owned by insiders.
Several hedge funds have recently bought and sold shares of RMD. Regent Peak Wealth Advisors LLC acquired a new stake in shares of ResMed during the fourth quarter worth approximately $30,000. Capital Asset Advisory Services LLC acquired a new stake in ResMed in the fourth quarter valued at approximately $34,000. International Assets Investment Management LLC acquired a new stake in ResMed in the fourth quarter valued at approximately $37,000. JJJ Advisors Inc. lifted its stake in ResMed by 435.3% in the fourth quarter. JJJ Advisors Inc. now owns 182 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 148 shares during the last quarter. Finally, Bainco International Investors acquired a new stake in ResMed in the fourth quarter valued at approximately $43,000. Institutional investors and hedge funds own 68.64% of the company’s stock.
NYSE:RMD traded up $0.83 during mid-day trading on Monday, hitting $197.12. The stock had a trading volume of 631,316 shares, compared to its average volume of 670,034. The stock has a market capitalization of $28.68 billion, a price-to-earnings ratio of 42.30, a P/E/G ratio of 2.86 and a beta of 0.28. The company has a 50 day simple moving average of $191.34 and a 200-day simple moving average of $198.47. ResMed has a 52 week low of $149.16 and a 52 week high of $224.43. The company has a current ratio of 2.61, a quick ratio of 1.80 and a debt-to-equity ratio of 0.39.
ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 28th. The medical equipment provider reported $1.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.19. The firm had revenue of $800.00 million for the quarter, compared to the consensus estimate of $785.07 million. ResMed had a net margin of 22.45% and a return on equity of 30.64%. ResMed’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the firm posted $1.21 EPS. As a group, equities research analysts anticipate that ResMed will post 5.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 18th. Stockholders of record on Thursday, February 11th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend was Wednesday, February 10th. ResMed’s dividend payout ratio (DPR) is currently 32.77%.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
Featured Story: What is the Quick Ratio?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.